文献速递腹部技术与安全PETCT

基于18F-FDG PET/CT的影像组学在预测非转移性结直肠癌神经周围侵犯及预后中的价值

The value of 18F-FDG PET/CT-based radiomics in predicting perineural invasion and outcome in non-metastatic colorectal cancer.
PubMed 文献 · Abdom Radiol (NY) · 2022-02-26

这项回顾性研究纳入131例非转移性结直肠癌患者,整合临床信息、PET/CT特征、代谢参数及影像组学构建列线图,用于术前预测神经周围侵犯(PNI)及预后。模型在训练队列AUC为0.90(95%CI: 0.83-0.97),测试队列AUC为0.80(95%CI: 0.65-0.95);列线图训练队列敏感度0.84、特异度0.83。N分期、PNI状态和列线图评分是无进展生存期(PFS)的独立预测因素。

要点

  • CEA、PET/CT淋巴结转移(N分期)和总病灶糖酵解(TLG)是PNI的独立预测因素(p<0.05)。
  • 整合临床、PET/CT特征、代谢参数和影像组学的列线图训练队列AUC 0.90、测试队列AUC 0.80。
  • 列线图训练队列敏感度0.84、特异度0.83;临床模型训练队列敏感度0.66、特异度0.85。

核心结论

  • 整合临床数据、PET/CT特征、代谢参数和影像组学的列线图在预测非转移性结直肠癌PNI状态方面表现良好,并与患者结局相关。

研究设计与样本

  • 回顾性研究,共纳入131例接受PET/CT扫描的非转移性结直肠癌患者。

关键影像表现/征象

  • PNI阳性组与PNI阴性组之间,基于所选CT影像组学特征和PET影像组学特征计算的Rad-score差异有统计学意义(p<0.001)。

诊断标准与关键数值

  • CEA、PET/CT淋巴结转移(N分期)和TLG是PNI的独立预测因素(p<0.05)。
  • 共选取6个CT影像组学特征和12个PET影像组学特征用于预测PNI。
  • 构建模型训练队列AUC为0.90(95%CI: 0.83-0.97),测试队列AUC为0.80(95%CI: 0.65-0.95)。
  • 列线图训练队列预测敏感度为0.84、特异度为0.83;临床模型训练队列预测敏感度为0.66、特异度为0.85。
  • N分期、PNI状态和Nomo-score是非转移性结直肠癌患者PFS的独立预测因素。

临床应用与阅片要点

  • 决策曲线分析(DCA)显示,使用该模型可使非转移性结直肠癌患者获得更多获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Perineural invasion (PNI) has been recognized as an important prognosis factor in patients with colorectal cancer (CRC). The purpose of this retrospective study was to investigate the value of 18F-FDG PET/CT-based radiomics integrating clinical information, PET/CT features, and metabolic parameters for preoperatively predicting PNI and outcome in non-metastatic CRC and establish an easy-to-use nomogram.

METHODS: A total of 131 patients with non-metastatic CRC who undergo PET/CT scan were retrospectively enrolled. Univariate analysis was used to compare the differences between PNI-present and PNI-absent groups. Multivariate logistic regression was performed to select the independent predictors for PNI status. Akaike information criterion (AIC) was used to select the best prediction models for PNI status. CT radiomics signatures (RSs) and PET-RSs were selected by maximum relevance minimum redundancy (mRMR) and the least absolute shrinkage and selection operator algorithm (LASSO) regression and radiomics scores (Rad-scores) were calculated for each patient. The prediction models with or without Rad-score were established. According to the nomogram, nomogram scores (Nomo-scores) were calculated for each patient. The performance of different models was assessed with the area under the curve (AUC), specificity, and sensitivity. The clinical usefulness was assessed by decision curve (DCA). Multivariate Cox regression was used to selected independent predictors of progression-free survival (PFS).

RESULTS: Among all the clinical information, PET/CT features, and metabolic parameters, CEA, lymph node metastatic on PET/CT (N stage), and total lesion glycolysis (TLG) were independent predictors for PNI (p < 0.05). Six CT-RSs and 12 PET-RSs were selected as the most valuable factors to predict PNI. The Rad-score calculated with these RSs was significantly different between PNI-present and PNI-absent groups (p < 0.001). The AUC of the constructed model was 0.90 (95%CI: 0.83-0.97) in the training cohort and 0.80 (95%CI: 0.65-0.95) in the test cohort. The nomogram's predicting sensitivity was 0.84 and the specificity was 0.83 in the training cohort. The clinical model's predicting sensitivity and specificity were 0.66 and 0.85 in the training cohort, respectively. Besides, DCA showed that patients with non-metastatic CRC could get more benefit with our model. The results also indicated that N stage, PNI status, and the Nomo-score were independent predictors of PFS in patients with non-metastatic CRC.

CONCLUSION: The nomogram, integrating clinical data, PET/CT features, metabolic parameters, and radiomics, performs well in predicting PNI status and is associated with the outcome in patients with non-metastatic CRC.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Ma, Guo, Miao, et al. The value of 18F-FDG PET/CT-based radiomics in predicting perineural invasion and outcome in non-metastatic colorectal cancer. Abdom Radiol (NY). 2022. PMID: 35218381. doi:10.1007/s00261-022-03453-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。